JP Morgan Chase’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

JP Morgan Chase’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$3	–	7831
2024 Q3	$3	Hold	1	–	–	﹤0.01%	7350
2024 Q2	$4	Buy	+1	New	+$6	﹤0.01%	7259
2024 Q1	–	Hold	0	–	–	–	7349
2022 Q3	–	Hold	0	–	–	–	6937
2022 Q2	–	Hold	0	–	–	–	6971
2021 Q3	–	Sell	-1	Closed	-$2K	–	6882
2021 Q2	$2K	Sell	1 -15	-94%	-$74K	﹤0.01%	6221
2021 Q1	$110K	Buy	16 +1	+7%	+$6.87K	﹤0.01%	5349
2020 Q4	$101K	Buy	15 +11	+275%	+$57.7K	﹤0.01%	4992
2020 Q3	$52K	Sell	4 -1	-20%	-$12.2K	﹤0.01%	4927
2020 Q2	$58K	Buy	+5	New	+$56.4K	﹤0.01%	4790

Other funds holding ATXI

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

JP Morgan Chase's ATXI Position: Q4 2024 in Review

JP Morgan Chase sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2024, closing a stake of 1 share — an estimated $3 sold.

JP Morgan Chase first reported a position in ATXI in Q2 2020 and held it in 7 quarters. The position peaked at $110K in Q1 2021. 7 funds tracked by Wall St. Rank hold ATXI as of Q4 2024.

JP Morgan Chase reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
JP Morgan Chase sold 1 Avenue Therapeutics, Inc. Common Stock share in Q4 2024, an estimated $3.
JP Morgan Chase first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
JP Morgan Chase's Avenue Therapeutics, Inc. Common Stock position peaked at $110K in Q1 2021.
7 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.